Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Shutdown of ER-associated degradation pathway rescues functions of mutant iduronate 2-sulfatase linked to mucopolysaccharidosis type II.

Cell death & disease | 2018

Mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome, is a devastating progressive disease caused by mutations in the iduronate 2-sulfatase (IDS) gene. IDS is one of the sulfatase enzymes required for lysosomal degradation of glycosaminoglycans. Mutant proteins linked to diseases are often prone to misfolding. These misfolded proteins accumulate in the endoplasmic reticulum (ER) and are degraded by the ubiquitin-proteasome pathway (ER-associated degradation (ERAD)). The decreased enzyme activities of IDS mutants may be due to accelerated degradation by ERAD. However, intracellular dynamics including degradation of IDS mutants is unexplored. In this report, we examined biochemical and biological characteristics of wild-type (WT) IDS and IDS mutants expressed in HeLa cells. IDS was shown to be glycosylated in the ER and Golgi apparatus and proteolytically cleaved to generate the mature forms in the Golgi apparatus. The mature WT IDS was translocated to the lysosome. In contrast, all IDS mutants we examined were found to accumulate in the ER and could not efficiently translocate to the lysosome. Accumulated IDS mutants in the ER were ubiquitinated by ERAD-related ubiquitin E3 ligase HRD1 followed by degradation via ERAD. Suppressed degradation of 'attenuated' mutant A85T IDS (the late-onset form of MPS II) by inhibiting ERAD components improved translocation to the lysosome and its activities. Our novel findings provide alternative targets to current principal therapies for MPS II. These perspectives provide a potenti al framework to develop fundamental therapeutic strategies and agents.

Pubmed ID: 30042467 RIS Download

Research resources used in this publication

Associated grants

None

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Thermo Fisher Scientific (tool)

RRID:SCR_008452

Commercial vendor and service provider of laboratory reagents and antibodies. Supplier of scientific instrumentation, reagents and consumables, and software services.

View all literature mentions

BD Biosciences (tool)

RRID:SCR_013311

An Antibody supplier

View all literature mentions

New England Biolabs (tool)

RRID:SCR_013517

An Antibody supplier

View all literature mentions

Millipore (tool)

RRID:SCR_008983

An Antibody supplier

View all literature mentions

Wako (tool)

RRID:SCR_013651

An Antibody supplier

View all literature mentions

HA-Tag (C29F4) Rabbit mAb (antibody)

RRID:AB_1549585

This monoclonal targets HA-Tag

View all literature mentions

Ubiquitin, mAb (P4D1) (antibody)

RRID:AB_10998070

This unknown targets Ubiquitin mAb (P4D1)

View all literature mentions

CD107b (antibody)

RRID:AB_396137

This monoclonal targets CD107b

View all literature mentions

Calnexin (C5C9) Rabbit mAb (antibody)

RRID:AB_2228381

This monoclonal targets CANX

View all literature mentions

DNAJB11 antibody (antibody)

RRID:AB_2094400

This polyclonal targets DNAJB11

View all literature mentions

CREB-2 (C-20) (antibody)

RRID:AB_2058752

This polyclonal targets ATF4

View all literature mentions

beta-Actin (AC-15) (antibody)

RRID:AB_1119529

This monoclonal targets beta-Actin (AC-15)

View all literature mentions

HeLa (cell line)

RRID:CVCL_0030

Cell line HeLa is a Cancer cell line with a species of origin Homo sapiens

View all literature mentions

HA-Tag (C29F4) Rabbit mAb (antibody)

RRID:AB_1549585

This monoclonal targets HA-Tag

View all literature mentions

Ubiquitin, mAb (P4D1) (antibody)

RRID:AB_10998070

This unknown targets Ubiquitin mAb (P4D1)

View all literature mentions

CD107b (antibody)

RRID:AB_396137

This monoclonal targets CD107b

View all literature mentions

Calnexin (C5C9) Rabbit mAb (antibody)

RRID:AB_2228381

This monoclonal targets CANX

View all literature mentions

DNAJB11 antibody (antibody)

RRID:AB_2094400

This polyclonal targets DNAJB11

View all literature mentions

CREB-2 (C-20) (antibody)

RRID:AB_2058752

This polyclonal targets ATF4

View all literature mentions

beta-Actin (AC-15) (antibody)

RRID:AB_1119529

This monoclonal targets beta-Actin (AC-15)

View all literature mentions

HeLa (cell line)

RRID:CVCL_0030

Cell line HeLa is a Cancer cell line with a species of origin Homo sapiens

View all literature mentions